MindBio Therapeutics Corp. (CSE:MBIO)
Canada flag Canada · Delayed Price · Currency is CAD
0.800
0.00 (0.00%)
At close: Mar 5, 2026

MindBio Therapeutics Cash Flow Statement

Millions AUD. Fiscal year is Jul - Jun.
Fiscal Year
TTM FY 2025 FY 2024 FY 2023 FY 2022
Period Ending
Dec '25 Jun '25 Jun '24 Jun '23 Jun '22
Net Income
-6.01-2.81-0.41-4.29-7.47
Asset Writedown & Restructuring Costs
0.590.59---
Loss (Gain) From Sale of Investments
--0.010.02-
Stock-Based Compensation
3.780.84-1.4-
Other Operating Activities
0.230.290.190.951.93
Change in Accounts Payable
0.460.6-0.06-0.40.87
Change in Unearned Revenue
---0.120.12-
Change in Other Net Operating Assets
00-0-0.01-0.04
Operating Cash Flow
-1.08-0.49-0.38-2.21-4.72
Cash Acquisitions
0.010.01---
Investment in Securities
-----0.03
Investing Cash Flow
0.010.01---0.03
Long-Term Debt Issued
----6.38
Long-Term Debt Repaid
--0.01-0.01-0.11-
Net Debt Issued (Repaid)
-0-0.01-0.01-0.116.38
Issuance of Common Stock
1.440.44-1.15-
Common Dividends Paid
-----0.79
Other Financing Activities
-0-00.28--
Financing Cash Flow
1.440.430.271.045.59
Foreign Exchange Rate Adjustments
-0.02-0.02-0.070.18-
Net Cash Flow
0.35-0.07-0.18-10.83
Levered Free Cash Flow
-0.26-0.71-0.79-1.39-
Unlevered Free Cash Flow
-0.04-0.34-0.57-1.11-
Change in Working Capital
0.410.6-0.17-0.290.82
Source: S&P Capital IQ. Standard template. Financial Sources.